1. The DALI vitamin D randomized controlled trial for gestational diabetes mellitus prevention: No major benefit shown besides vitamin D sufficiency.
- Author
-
Corcoy R, Mendoza LC, Simmons D, Desoye G, Adelantado JM, Chico A, Devlieger R, van Assche A, Galjaard S, Timmerman D, Lapolla A, Dalfra MG, Bertolotto A, Harreiter J, Wender-Ozegowska E, Zawiejska A, Kautzky-Willer A, Dunne FP, Damm P, Mathiesen ER, Jensen DM, Andersen LLT, Tanvig M, Hill DJ, Jelsma JG, Snoek FJ, Köfeler H, Trötzmüller M, Lips P, and van Poppel MNM
- Subjects
- Adult, Blood Glucose drug effects, Diabetes, Gestational blood, Europe, Female, Humans, Insulin blood, Pregnancy, Vitamin D administration & dosage, Vitamin D blood, Vitamins administration & dosage, Vitamins blood, Weight Gain drug effects, Diabetes, Gestational prevention & control, Dietary Supplements, Vitamin D pharmacology, Vitamins pharmacology
- Abstract
Background & Aims: As vitamin D deficiency is associated with an increased risk of gestational diabetes mellitus (GDM), we aimed to test vitamin D supplementation as a strategy to reduce GDM risk (evaluated after fasting plasma glucose (FPG), insulin resistance and weight gain) in pregnant overweight/obese women., Methods: The DALI vitamin D multicenter study enrolled women with prepregnancy body mass index (BMI) ≥ 29 kg/m
2 , ≤19 + 6 weeks of gestation and without GDM. Participants were randomized to receive 1600 IU/day vitamin D3 or placebo (each with or without lifestyle intervention) on top of (multi)vitamins supplements. Women were assessed for vitamin D status (sufficiency defined as serum 25-hydroxyvitamin D (25(OH)D) ≥ 50 nmol/l), FPG, insulin resistance and weight at baseline, 24-28 and 35-37 weeks. Linear or logistic regression analyses were performed to assess intervention effects., Results: Average baseline serum 25(OH)D was ≥50 nmol/l across all study sites. In the vitamin D intervention arm (n = 79), 97% of participants achieved target serum vitamin 25(OH)D (≥50 nmol/l) at 24-28 weeks and 98% at 35-37 weeks vs 74% and 78% respectively in the placebo arm (n = 75, p < 0.001). A small but significantly lower FPG (-0.14 mmol/l; CI95 -0.28, -0.00) was observed at 35-37 weeks with the vitamin D intervention without any additional difference in metabolic status, perinatal outcomes or adverse event rates., Conclusion: In the DALI vitamin D trial, supplementation with 1600 IU vitamin D3/day achieved vitamin D sufficiency in virtually all pregnant women and a small effect in FPG at 35-37 weeks. The potential of vitamin D supplementation for GDM prevention in vitamin D sufficient populations appears to be limited., Trial Registration Number: ISRCTN70595832., (Copyright © 2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF